PURPOSE: Multidrug resistance (MDR) has been linked to sphingolipid metabolism and preclinical data ascribe glucosylceramide synthase (GCS) a major role for MDR especially in breast cancer cells but no profound data are available on the expression of this potential therapeutic target in clinical breast cancer specimens. METHODS: We analyzed microarray data of GCS expression in a large cohort of 1,681 breast tumors. RESULTS: Expression of GCS was associated with a positive estrogen receptor (ER) status, lower histological grading, low Ki67 levels and ErbB2 negativity (P < 0.001 for all). In univariate analysis there was a benefit for disease free survival for patients with tumors displaying low levels of GCS expression but this significance was lost in multivariate Cox regression. CONCLUSIONS: Our results suggest ER positive tumors may be the most promising candidates for a potential therapeutic application of GCS inhibitors.
PURPOSE: Multidrug resistance (MDR) has been linked to sphingolipid metabolism and preclinical data ascribe glucosylceramide synthase (GCS) a major role for MDR especially in breast cancer cells but no profound data are available on the expression of this potential therapeutic target in clinical breast cancer specimens. METHODS: We analyzed microarray data of GCS expression in a large cohort of 1,681 breast tumors. RESULTS: Expression of GCS was associated with a positive estrogen receptor (ER) status, lower histological grading, low Ki67 levels and ErbB2 negativity (P < 0.001 for all). In univariate analysis there was a benefit for disease free survival for patients with tumors displaying low levels of GCS expression but this significance was lost in multivariate Cox regression. CONCLUSIONS: Our results suggest ER positive tumors may be the most promising candidates for a potential therapeutic application of GCS inhibitors.
Authors: Christine Desmedt; Fanny Piette; Sherene Loi; Yixin Wang; Françoise Lallemand; Benjamin Haibe-Kains; Giuseppe Viale; Mauro Delorenzi; Yi Zhang; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian L Harris; Jan G M Klijn; John A Foekens; Fatima Cardoso; Martine J Piccart; Marc Buyse; Christos Sotiriou Journal: Clin Cancer Res Date: 2007-06-01 Impact factor: 12.531
Authors: Andy J Minn; Gaorav P Gupta; David Padua; Paula Bos; Don X Nguyen; Dimitry Nuyten; Bas Kreike; Yi Zhang; Yixin Wang; Hemant Ishwaran; John A Foekens; Marc van de Vijver; Joan Massagué Journal: Proc Natl Acad Sci U S A Date: 2007-04-09 Impact factor: 11.205
Authors: Yudi Pawitan; Judith Bjöhle; Lukas Amler; Anna-Lena Borg; Suzanne Egyhazi; Per Hall; Xia Han; Lars Holmberg; Fei Huang; Sigrid Klaar; Edison T Liu; Lance Miller; Hans Nordgren; Alexander Ploner; Kerstin Sandelin; Peter M Shaw; Johanna Smeds; Lambert Skoog; Sara Wedrén; Jonas Bergh Journal: Breast Cancer Res Date: 2005-10-03 Impact factor: 6.466
Authors: Anna Maria Calcagno; Crystal D Salcido; Jean-Pierre Gillet; Chung-Pu Wu; Jennifer M Fostel; Melanie D Mumau; Michael M Gottesman; Lyuba Varticovski; Suresh V Ambudkar Journal: J Natl Cancer Inst Date: 2010-10-08 Impact factor: 13.506
Authors: Gauri A Patwardhan; Qian-Jin Zhang; Dongmei Yin; Vineet Gupta; Jianxiong Bao; Can E Senkal; Besim Ogretmen; Myles C Cabot; Girish V Shah; Paul W Sylvester; S Michal Jazwinski; Yong-Yu Liu Journal: PLoS One Date: 2009-09-09 Impact factor: 3.240